Jan Muntel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jan Muntel has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Lukas Reiter
Biognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland
6 shared publications - Roland Bruderer
Biognosys AG, Wagistrasse 21, 8952 Schlieren, Switzerland
5 shared publications - Christoph N. Schlaffner
Hasso Plattner Institute, Digital Engineering Faculty, University of Potsdam , 14482 Potsdam
2 shared publications - Hanno Steen
Boston Children's Hospital
2 shared publications Melissa S. Rotunno
Department of Pathology, Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
2 shared publications- Olga Vitek
Northeastern University
2 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (13) , 4058-4073
Centrifugal microfluidic automation of the protein aggregation capture workflow for robust mass spectrometry-based proteomics
The AutoPAC-disk is a centrifugal microfluidic disk for protein aggregation capture-based sample preparation in bottom-up proteomics, enabling automated on-bead proteolysis with pre-stored buffers.
- 15 June 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (13) , 4058-4073
Open AccessCentrifugal microfluidic automation of the protein aggregation capture workflow for robust mass spectrometry-based proteomics
The AutoPAC-disk is a centrifugal microfluidic disk for protein aggregation capture-based sample preparation in bottom-up proteomics, enabling automated on-bead proteolysis with pre-stored buffers.
- 12 October 2022
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 29 (10) , 978-989
Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker
- 12 October 2022
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 29 (10) , 978-989
Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker
- Open Access
- 24 January 2022
- Published by S. Karger AG in Neonatology
- Vol. 119 (2) , 193-203
Urine Proteomics for Noninvasive Monitoring of Biomarkers in Bronchopulmonary Dysplasia
Introduction: Current techniques to diagnose and/or monitor critically ill neonates with bronchopulmonary dysplasia (BPD) require invasive sampling of body fluids, which is suboptimal in these frail neonates. We tested our hypothesis that it is feasible to use noninvasively collected urine samples for proteomics from extremely low gestational age newborns (ELGANs) at risk for BPD to confirm previously identified proteins and biomarkers associated with BPD. Methods: We developed a robust high-throughput urine proteomics methodology that requires only 50 μL of urine. We utilized the methodology with a proof-of-concept study validating proteins previously identified in invasively collected sample types such as blood and/or tracheal aspirates on urine collected within 72 h of birth from ELGANs (gestational age [26 ± 1.2] weeks) who were admitted to a single Neonatal Intensive Care Unit (NICU), half of whom eventually developed BPD (n = 21), while the other half served as controls (n = 21). Results: Our high-throughput urine proteomics approach clearly identified several BPD-associated changes in the urine proteome recapitulating expected blood proteome changes, and several urinary proteins predicted BPD risk. Interestingly, 16 of the identified urinary proteins are known targets of drugs approved by the Food and Drug Administration. Conclusion: In addition to validating numerous proteins, previously found in invasively collected blood, tracheal aspirate, and bronchoalveolar lavage, that have been implicated in BPD pathophysiology, urine proteomics also suggested novel potential therapeutic targets. Ease of access to urine could allow for sequential proteomic evaluations for longitudinal monitoring of disease progression and impact of therapeutic intervention in future studies.
- 24 January 2022
- Published by S. Karger AG in Neonatology
- Vol. 119 (2) , 193-203
Open AccessUrine Proteomics for Noninvasive Monitoring of Biomarkers in Bronchopulmonary Dysplasia
Introduction: Current techniques to diagnose and/or monitor critically ill neonates with bronchopulmonary dysplasia (BPD) require invasive sampling of body fluids, which is suboptimal in these frail neonates. We tested our hypothesis that it is feasible to use noninvasively collected urine samples for proteomics from extremely low gestational age newborns (ELGANs) at risk for BPD to confirm previously identified proteins and biomarkers associated with BPD. Methods: We developed a robust high-throughput urine proteomics methodology that requires only 50 μL of urine. We utilized the methodology with a proof-of-concept study validating proteins previously identified in invasively collected sample types such as blood and/or tracheal aspirates on urine collected within 72 h of birth from ELGANs (gestational age [26 ± 1.2] weeks) who were admitted to a single Neonatal Intensive Care Unit (NICU), half of whom eventually developed BPD (n = 21), while the other half served as controls (n = 21). Results: Our high-throughput urine proteomics approach clearly identified several BPD-associated changes in the urine proteome recapitulating expected blood proteome changes, and several urinary proteins predicted BPD risk. Interestingly, 16 of the identified urinary proteins are known targets of drugs approved by the Food and Drug Administration. Conclusion: In addition to validating numerous proteins, previously found in invasively collected blood, tracheal aspirate, and bronchoalveolar lavage, that have been implicated in BPD pathophysiology, urine proteomics also suggested novel potential therapeutic targets. Ease of access to urine could allow for sequential proteomic evaluations for longitudinal monitoring of disease progression and impact of therapeutic intervention in future studies.
- Open Access
Biomarker Candidates for Tumors Identified from Deep-Profiled Plasma Stem Predominantly from the Low Abundant Area
The plasma proteome has the potential to enable a holistic analysis of the health state of an individual. However, plasma biomarker discovery is difficult due to its high dynamic range and variability. Here, we present a novel automated analytical approach for deep plasma profiling and applied it to a 180-sample cohort of human plasma from lung, breast, colorectal, pancreatic, and prostate cancer. Using a controlled quantitative experiment, we demonstrate a 257% increase in protein identification and a 263% increase in significantly differentially abundant proteins over neat plasma. In the cohort, we identified 2,732 proteins. Using machine learning, we discovered biomarker candidates such as STAT3 in colorectal cancer and developed models that classify the disease state. For pancreatic cancer, a separation by stage was achieved. Importantly, biomarker candidates came predominantly from the low abundance region, demonstrating the necessity to deeply profile because they would have been missed by shallow profiling.
Open AccessBiomarker Candidates for Tumors Identified from Deep-Profiled Plasma Stem Predominantly from the Low Abundant Area
The plasma proteome has the potential to enable a holistic analysis of the health state of an individual. However, plasma biomarker discovery is difficult due to its high dynamic range and variability. Here, we present a novel automated analytical approach for deep plasma profiling and applied it to a 180-sample cohort of human plasma from lung, breast, colorectal, pancreatic, and prostate cancer. Using a controlled quantitative experiment, we demonstrate a 257% increase in protein identification and a 263% increase in significantly differentially abundant proteins over neat plasma. In the cohort, we identified 2,732 proteins. Using machine learning, we discovered biomarker candidates such as STAT3 in colorectal cancer and developed models that classify the disease state. For pancreatic cancer, a separation by stage was achieved. Importantly, biomarker candidates came predominantly from the low abundance region, demonstrating the necessity to deeply profile because they would have been missed by shallow profiling.
- Open Access
- 7 December 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
FLEXIQuant-LF to quantify protein modification extent in label-free proteomics data
Improvements in LC-MS/MS methods and technology have enabled the identification of thousands of modified peptides in a single experiment. However, protein regulation by post-translational modifications (PTMs) is not binary, making methods to quantify the modification extent crucial to understanding the role of PTMs. Here, we introduce FLEXIQuant-LF, a software tool for large-scale identification of differentially modified peptides and quantification of their modification extent without knowledge of the types of modifications involved. We developed FLEXIQuant-LF using label-free quantification of unmodified peptides and robust linear regression to quantify the modification extent of peptides. As proof of concept, we applied FLEXIQuant-LF to data-independent-acquisition (DIA) data of the anaphase promoting complex/cyclosome (APC/C) during mitosis. The unbiased FLEXIQuant-LF approach to assess the modification extent in quantitative proteomics data provides a better understanding of the function and regulation of PTMs. The software is available at https://github.com/SteenOmicsLab/FLEXIQuantLF.
- 7 December 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Open AccessFLEXIQuant-LF to quantify protein modification extent in label-free proteomics data
Improvements in LC-MS/MS methods and technology have enabled the identification of thousands of modified peptides in a single experiment. However, protein regulation by post-translational modifications (PTMs) is not binary, making methods to quantify the modification extent crucial to understanding the role of PTMs. Here, we introduce FLEXIQuant-LF, a software tool for large-scale identification of differentially modified peptides and quantification of their modification extent without knowledge of the types of modifications involved. We developed FLEXIQuant-LF using label-free quantification of unmodified peptides and robust linear regression to quantify the modification extent of peptides. As proof of concept, we applied FLEXIQuant-LF to data-independent-acquisition (DIA) data of the anaphase promoting complex/cyclosome (APC/C) during mitosis. The unbiased FLEXIQuant-LF approach to assess the modification extent in quantitative proteomics data provides a better understanding of the function and regulation of PTMs. The software is available at https://github.com/SteenOmicsLab/FLEXIQuantLF.
- 14 September 2020
- Published by Springer Nature in Nature Methods
- Vol. 17 (10) , 981-984
MassIVE.quant: a community resource of quantitative mass spectrometry–based proteomics datasets
MassIVE.quant is a repository infrastructure and data resource for reproducible quantitative mass spectrometry–based proteomics, which is compatible with all mass spectrometry data acquisition types and computational analysis tools. A branch structure enables MassIVE.quant to systematically store raw experimental data, metadata of the experimental design, scripts of the quantitative analysis workflow, intermediate input and output files, as well as alternative reanalyses of the same dataset.
- 14 September 2020
- Published by Springer Nature in Nature Methods
- Vol. 17 (10) , 981-984
MassIVE.quant: a community resource of quantitative mass spectrometry–based proteomics datasets
MassIVE.quant is a repository infrastructure and data resource for reproducible quantitative mass spectrometry–based proteomics, which is compatible with all mass spectrometry data acquisition types and computational analysis tools. A branch structure enables MassIVE.quant to systematically store raw experimental data, metadata of the experimental design, scripts of the quantitative analysis workflow, intermediate input and output files, as well as alternative reanalyses of the same dataset.
- Open Access
- 1 February 2020
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 19 (2) , 421-430
Combining Precursor and Fragment Information for Improved Detection of Differential Abundance in Data Independent Acquisition
- 1 February 2020
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 19 (2) , 421-430
Open AccessCombining Precursor and Fragment Information for Improved Detection of Differential Abundance in Data Independent Acquisition
- 18 November 2019
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 19 (1) , 371-381
Systematic Comparison of Strategies for the Enrichment of Lysosomes by Data Independent Acquisition
In mammalian cells, the lysosome is the main organelle for the degradation of macromolecules and the recycling of their building blocks. Correct lysosomal function is essential, and mutations in every known lysosomal hydrolase result in so-called lysosomal storage disorders, a group of rare and often fatal inherited diseases. Furthermore, it is becoming more and more apparent, that lysosomes play also decisive roles in other diseases, such as cancer and common neurodegenerative disorders. This leads to an increasing interest in the proteomic analysis of lysosomes, for which enrichment is a prerequisite. In this study, we compared the four most common strategies for the enrichment of lysosomes using data independent acquisition. We performed centrifugation at 20,000 x g to generate an organelle enriched pellet, two-step sucrose density gradient centrifugation, enrichment by superparamagnetic iron oxide nanoparticles (SPIONs), and immunoprecipitation using a 3xHA tagged version of the lysosomal membrane protein TMEM192. Our results show, that SPIONs and TMEM192-immunoprecipitation outperform the other approaches with enrichment factors of up to 118-fold for certain proteins relative to whole cell lysates. Furthermore, we achieved an increase in identified lysosomal proteins and a higher reproducibility in protein intensities for label free quantification in comparison to the other strategies.
- 18 November 2019
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 19 (1) , 371-381
Systematic Comparison of Strategies for the Enrichment of Lysosomes by Data Independent Acquisition
In mammalian cells, the lysosome is the main organelle for the degradation of macromolecules and the recycling of their building blocks. Correct lysosomal function is essential, and mutations in every known lysosomal hydrolase result in so-called lysosomal storage disorders, a group of rare and often fatal inherited diseases. Furthermore, it is becoming more and more apparent, that lysosomes play also decisive roles in other diseases, such as cancer and common neurodegenerative disorders. This leads to an increasing interest in the proteomic analysis of lysosomes, for which enrichment is a prerequisite. In this study, we compared the four most common strategies for the enrichment of lysosomes using data independent acquisition. We performed centrifugation at 20,000 x g to generate an organelle enriched pellet, two-step sucrose density gradient centrifugation, enrichment by superparamagnetic iron oxide nanoparticles (SPIONs), and immunoprecipitation using a 3xHA tagged version of the lysosomal membrane protein TMEM192. Our results show, that SPIONs and TMEM192-immunoprecipitation outperform the other approaches with enrichment factors of up to 118-fold for certain proteins relative to whole cell lysates. Furthermore, we achieved an increase in identified lysosomal proteins and a higher reproducibility in protein intensities for label free quantification in comparison to the other strategies.
- Top Cited PapersOpen Access
- 29 August 2019
- Published by Oxford University Press (OUP) in Molecular Omics
- Vol. 15 (5) , 348-360
Surpassing 10 000 identified and quantified proteins in a single run by optimizing current LC-MS instrumentation and data analysis strategy
Comprehensive proteome quantification is crucial for a better understanding of underlying mechanisms of diseases. Liquid chromatography mass spectrometry (LC-MS) has become the method of choice for comprehensive proteome quantification due to its power and versatility. Even though great advances have been made in recent years, full proteome coverage for complex samples remains challenging due to the high dynamic range of protein expression. Additionally, when studying disease regulatory proteins, biomarkers or potential drug targets are often low abundant, such as for instance kinases and transcription factors. Here, we show that with improvements in chromatography and data analysis the single shot proteome coverage can go beyond 10 000 proteins in human tissue. In a testis cancer study, we quantified 11 200 proteins using data independent acquisition (DIA). This depth was achieved with a false discovery rate of 1% which was experimentally validated using a two species test. We introduce the concept of hybrid libraries which combines the strength of direct searching of DIA data as well as the use of large project-specific or published DDA data sets. Remarkably deep proteome coverage is possible using hybrid libraries without the additional burden of creating a project-specific library. Within the testis cancer set, we found a large proportion of proteins in an altered expression (in total: 3351; 1453 increased in cancer). Many of these proteins could be linked to the hallmarks of cancer. For example, the complement system was downregulated which helps to evade the immune response and chromosomal replication was upregulated indicating a dysregulated cell cycle.
- 29 August 2019
- Published by Oxford University Press (OUP) in Molecular Omics
- Vol. 15 (5) , 348-360
Top Cited PapersOpen AccessSurpassing 10 000 identified and quantified proteins in a single run by optimizing current LC-MS instrumentation and data analysis strategy
Comprehensive proteome quantification is crucial for a better understanding of underlying mechanisms of diseases. Liquid chromatography mass spectrometry (LC-MS) has become the method of choice for comprehensive proteome quantification due to its power and versatility. Even though great advances have been made in recent years, full proteome coverage for complex samples remains challenging due to the high dynamic range of protein expression. Additionally, when studying disease regulatory proteins, biomarkers or potential drug targets are often low abundant, such as for instance kinases and transcription factors. Here, we show that with improvements in chromatography and data analysis the single shot proteome coverage can go beyond 10 000 proteins in human tissue. In a testis cancer study, we quantified 11 200 proteins using data independent acquisition (DIA). This depth was achieved with a false discovery rate of 1% which was experimentally validated using a two species test. We introduce the concept of hybrid libraries which combines the strength of direct searching of DIA data as well as the use of large project-specific or published DDA data sets. Remarkably deep proteome coverage is possible using hybrid libraries without the additional burden of creating a project-specific library. Within the testis cancer set, we found a large proportion of proteins in an altered expression (in total: 3351; 1453 increased in cancer). Many of these proteins could be linked to the hallmarks of cancer. For example, the complement system was downregulated which helps to evade the immune response and chromosomal replication was upregulated indicating a dysregulated cell cycle.